Tablet Coating Reduces Production Times
The Opadry QX from Colorcon is suitable for tablets containing temperature-sensitive active ingredients.
The Opadry QX is a new, flexible, thin film tablet coating developed by Colorcon. Opadry can be applied over a broad range of process conditions and is suitable for tablets containing temperature-sensitive active ingredients. The high solids, low viscosity ingredients of Opadry QX allow coating across a broad range of process parameters in any type of coating equipment, Colorcon said on its website. The coating can also help reduces production and preparation times, the company said in an April 21, 2016 press announcement.
“Colorcon carried out extensive studies that clearly demonstrate the process adaptability of Opadry QX,” said Jason Teckoe, senior manager, Product Development at Colorcon in a press announcement. “The results confirm that Opadry QX provides operators with broader latitude to manage critical settings for optimal film coating such as tablet bed temperatures, spray, or air flow rates.”
Source: Colorcon
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
